You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

EPTIFIBATIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Eptifibatide patents expire, and when can generic versions of Eptifibatide launch?

Eptifibatide is a drug marketed by Accord Hlthcare, Amneal Pharms, Baxter Hlthcare Corp, Eugia Pharma, Hong Kong, Hybio, Mylan Labs Ltd, Rising, Sagent Pharms Inc, Shuangcheng, Slate Run Pharma, Teva Pharms Usa, and USV. and is included in fifteen NDAs.

The generic ingredient in EPTIFIBATIDE is eptifibatide. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the eptifibatide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Eptifibatide

A generic version of EPTIFIBATIDE was approved as eptifibatide by TEVA PHARMS USA on June 12th, 2015.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for EPTIFIBATIDE?
  • What are the global sales for EPTIFIBATIDE?
  • What is Average Wholesale Price for EPTIFIBATIDE?
Drug patent expirations by year for EPTIFIBATIDE
Drug Prices for EPTIFIBATIDE

See drug prices for EPTIFIBATIDE

Recent Clinical Trials for EPTIFIBATIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Baylor College of MedicinePhase 1/Phase 2
Assiut UniversityPhase 1/Phase 2
National Institute of Neurological Disorders and Stroke (NINDS)Phase 3

See all EPTIFIBATIDE clinical trials

Pharmacology for EPTIFIBATIDE
Paragraph IV (Patent) Challenges for EPTIFIBATIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
INTEGRILIN Injection eptifibatide 2 mg/mL, 100 mL vial 020718 1 2008-12-18
INTEGRILIN Injection eptifibatide 2 mg/mL, 10 mL vial 020718 1 2008-09-30

US Patents and Regulatory Information for EPTIFIBATIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare EPTIFIBATIDE eptifibatide INJECTABLE;INJECTION 205557-001 Nov 6, 2017 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sagent Pharms Inc EPTIFIBATIDE eptifibatide INJECTABLE;INJECTION 204693-002 Mar 7, 2018 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Pharms Usa EPTIFIBATIDE eptifibatide INJECTABLE;INJECTION 091555-001 Jun 5, 2015 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for EPTIFIBATIDE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Accord Healthcare S.L.U. Eptifibatide Accord eptifibatide EMEA/H/C/004104
Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty).
Authorised yes no no 2016-01-11
GlaxoSmithKline (Ireland) Limited Integrilin eptifibatide EMEA/H/C/000230
Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin.Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes.Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA).
Authorised no no no 1999-07-01
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.